TY - JOUR
T1 - Featured updates to the NCCN guidelines
AU - Motzer, Robert J.
AU - Jonasch, Eric
AU - Dror Michaelson, M.
AU - Nandagopal, Lakshminarayanan
AU - Gore, John L.
AU - George, Saby
AU - Alva, Ajjai
AU - Haas, Naomi
AU - Harrison, Michael R.
AU - Plimack, Elizabeth R.
AU - Sosman, Jeffrey
AU - Agarwal, Neeraj
AU - Bhayani, Sam
AU - Choueiri, Toni K.
AU - Costello, Brian A.
AU - Derweesh, Ithaar H.
AU - Gallagher, Thomas H.
AU - Hancock, Steven L.
AU - Kyriakopoulos, Christos
AU - LaGrange, Chad
AU - Lam, Elaine T.
AU - Lau, Clayton
AU - Lewis, Bryan
AU - Manley, Brandon
AU - McCreery, Brittany
AU - McDonald, Andrew
AU - Mortazavi, Amir
AU - Pierorazio, Phillip M.
AU - Ponsky, Lee
AU - Redman, Bruce G.
AU - Somer, Bradley
AU - Wile, Geoffrey
AU - Dwyer, Mary A.
AU - Hammond, Lydia J.
AU - Zuccarino-Catania, Griselda
N1 - Funding Information:
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.
Funding Information:
John L. Gore, MD, MS, Panel Member, has disclosed that he receives grant/research support from Ferring Pharmaceuticals, Inc. Saby George, MD, Panel Member, has disclosed that he receives grant/research support from Agensys Inc.; Astellas Pharma US, Inc.; Bayer Healthcare; Bristol-Myers Squibb Company; Eisai Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Seattle Genetics, Inc. He also receives consulting fees from Bristol-Myers Squibb Company, EMD Serano, Exelixis Inc., and Pfizer Inc. Ajjai Alva, MBBS, Panel Member, has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Bristol-Myers Squibb Company, Clovis Oncology, Janssen Pharmaceutica Products, LP, Merck & Co., Inc., Esanik, Ionis, Progfenics, and Prometheus; and that he receives consulting fees from AstraZeneca Pharmaceuticals LP, Bayer HealthCare, Merck & Co., Inc., and Progfenics. Naomi Haas, MD, Panel Member, has disclosed that she was a scientific advisor for Pfizer Inc., and Roche Laboratories, Inc. Michael R. Harrison, MD, Panel Member, has disclosed that he receives honoraria from Bayer HealthCare; receives grant/research support from Bristol-Myers Squibb Company, Exelixis Inc., Merck & Co., Inc., and Pfizer Inc.; receives consulting fees from Exelixis Inc., Genentech, Inc., and Janssen Pharmaceutica Products, LP; and is a scientific advisor for Fujifilm Corporation and Exelixis Inc. Elizabeth R. Plimack, MD, MS, Panel Member, has disclosed that she receives grant/research support from Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Peloton Therapeutics, Inc., and Pfizer Inc.; and is a scientific advisor for and receives consulting fees from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Flatiron Health, Inc., Janssen Pharmaceutica Products, LP, Pfizer Inc., and Seattle Genetics, Inc. Jeffrey Sosman, MD, Panel Member, has disclosed that he receives consulting fees from Genentech, Inc., and is a scientific advisor for and receives honoraria from Bristol-Myers Squibb Company. Mary A. Dwyer, MS, CGC, Senior Manager, Guidelines, NCCN, has disclosed that she has no relevant financial relationships. Lydia J. Hammond, MBA, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships. Griselda Zuccarino-Catania, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc. To view all of the conflicts of interest for the NCCN Guidelines panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.
Funding Information:
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Publisher Copyright:
© 2019. All rights reserved.
PY - 2019
Y1 - 2019
N2 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.
AB - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85075500785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075500785&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2019.0054
DO - 10.6004/jnccn.2019.0054
M3 - Review article
C2 - 31693980
AN - SCOPUS:85075500785
SN - 1540-1405
VL - 17
SP - 1278
EP - 1285
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 11
ER -